Sosei Group Corporation ( (SOLTF) ) has released its Q4 earnings. Here is a breakdown of the information Sosei Group Corporation presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nxera Pharma Co., Ltd., formerly known as Sosei Group Corporation, is a technology-driven biopharmaceutical company that focuses on drug discovery, development, and commercialization, particularly targeting G Protein-Coupled Receptors (GPCRs) for unmet medical needs globally. In its latest earnings report, Nxera Pharma announced significant revenue growth, achieving JPY 28,835 million for the year ending December 31, 2024, a substantial increase from the previous year. The company reported a core operating profit of JPY 3,606 million, contrasting with a core operating loss in the prior year, despite an IFRS operating loss of JPY 5,423 million due to increased operating expenses. Key strategic highlights included the approval and launch of QUVIVIQ™ in Japan, new partnerships, and expanded clinical trials, contributing to its robust pipeline. Looking ahead, Nxera Pharma remains focused on leveraging its NxWave™ platform and strategic partnerships to continue advancing its pipeline and delivering innovative therapies to meet global medical needs.